Additions:
Two studies in the May issue of the Journal of Clinical Investigation from researchers at DNAX Research Inc. and Schering-Plough Biopharma, in Palo Alto, California, demonstrate that blocking IL-23, which promotes the differentiation of destructive T cells, and its downstream factor IL-17 can significantly suppress the development of IBD and MS in mice.
Deletions:
Two studies in the May issue of the Journal of Clinical Investigation from researchers at DNAX Research Inc. and Schering-Plough Biopharma, in Palo Alto, California, demonstrate that blocking IL-23, which promotes the differentiation of destructive [[TCellInfo T cells]], and its downstream factor IL-17 can significantly suppress the development of IBD and MS in mice.
